AnaptysBio (ANAB) has attracted fresh attention after recent share price moves, prompting investors to reassess how its clinical-stage immunology pipeline and current valuation fit into their broader biotech exposure.

Recent trading has cooled slightly, with the share price down 3.3% over the past week and 1.9% over the past month. However, the year to date share price return of 28.5% and very large 1 year total shareholder return of about 4.3x suggest momentum has broadly been building as investors reassess both growth prospects and risk.

If AnaptysBio has you rethinking where you are taking risk in healthcare, it can be useful to compare it with other biotech opportunities using the Simply Wall St screener for 34 healthcare AI stocks

With AnaptysBio trading at $57.77 against an analyst price target near $84 and an intrinsic value estimate suggesting a large discount, investors have to ask: is there real upside left here, or is future growth already fully priced in?

Preferred Price-to-Sales of 7.2x: Is It Justified?

AnaptysBio trades on a P/S of 7.2x, which looks low against peers yet above its own estimated fair ratio, so the current share price implies a mixed valuation signal.

The P/S ratio compares the company’s market value to its revenue and is often used for unprofitable biotechs where earnings are still negative. For AnaptysBio, this matters because the business is still loss making, with a reported net loss of $26.8m despite revenue of $232.4m. Investors are therefore effectively paying for revenue today and potential profitability later.

On one hand, AnaptysBio is described as good value on P/S versus both the US Biotechs industry average of 10.7x and a broader peer group at 29x. This points to a discount relative to comparable stocks. On the other hand, the same analysis flags that the current 7.2x P/S looks expensive versus an estimated fair P/S ratio of 4.6x, a level the market could move toward if sentiment or growth expectations cool.

This tension is important if you are benchmarking AnaptysBio against other biotechs with strong pipelines, cash positions and revenue visibility, or against a wider set of stocks with solid balance sheets and fundamentals via a broader screener such as the solid balance sheet and fundamentals stocks screener (46 results)

Result: Price-to-Sales of 7.2x (UNDERVALUED)

However, the story can change quickly if clinical trial data disappoints or if collaboration milestones with partners like GSK and Vanda slip or are reprioritised.

Another View: Our DCF Model Paints A Different Picture

While the P/S of 7.2x looks relatively restrained, the Simply Wall St DCF model presents a different perspective. It indicates an estimated future cash flow value of $356.74 per share compared with today’s $57.77. That gap suggests a much deeper discount, but it is important to consider how comfortable you are with the assumptions behind it.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out AnaptysBio for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 46 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Given the mix of risks and potential rewards highlighted above, the next step is to look through the underlying data yourself and decide how comfortable you are with the balance of uncertainty and opportunity here, then weigh that against the 2 key rewards and 2 important warning signs

Looking for more investment ideas?

If AnaptysBio has sharpened your focus, do not stop here. Broaden your watchlist with other focused stock ideas built from the same underlying data.

• Target potential mispricings by scanning companies flagged as quality but overlooked through the 46 high quality undervalued stocks.
• Prioritise resilience by screening for businesses that score well on financial strength using the 65 resilient stocks with low risk scores.
• Spot fresh opportunities early by reviewing the screener containing 22 high quality undiscovered gems before they attract wider attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.